FACULTY

William Bensinger, MD  CHAIR
Director, Myeloma Program
Myeloma & Transplant Program
Swedish Cancer Center
Seattle, WA

Ajay Nooka, MD, MPH, FACP
Associate Professor
Department of Hematology and Medical Oncology
Emory University School of Medicine
Atlanta, GA

Ajai Chari, MD
Associate Professor of Medicine
Mount Sinai School of Medicine
New York, NY

Krina Patel, MD, MSc
Assistant Professor
Department of Lymphoma/Myeloma
MD Anderson Cancer Center
Houston, TX

Sarah A. Holstein, MD, PhD
Associate Professor of Medicine
Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, NE

Paul Richardson, MD  CHAIR
Clinical Program Leader & Director of Clinical Research
Dana-Farber Cancer Institute
Boston, MA

Amrita Krishnan, MD
Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research
Professor
Department of Hematology & Hematopoietic Cell Transplantation
City of Hope National Medical Center
Los Angeles, CA

Edward Stadtmauer, MD
Section Chief, Hematologic Malignancies
University of Pennsylvania
Philadelphia, PA

Sarah A. Holstein, MD, PhD
Associate Professor of Medicine
Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, NE

Krina Patel, MD, MSc
Assistant Professor
Department of Lymphoma/Myeloma
MD Anderson Cancer Center
Houston, TX

Sagar Lonial, MD, FACP
Professor and Chair
Department of Hematology and Medical Oncology
Winship Cancer Institute
Emory University
Atlanta, GA

Keith Stewart, MB, ChB
Carlson and Nelson Endowed Director
Center for Individualized Medicine
Vasek and Anna Maria Polak Professor of Cancer Research
Mayo Clinic
Pheonix, AZ

Sagar Lonial, MD, FACP
Professor and Chair
Department of Hematology and Medical Oncology
Winship Cancer Institute
Emory University
Atlanta, GA

Frits Van Rhee, MD, PhD
Professor of Medicine
Clinical Director of the UAMS Myeloma Center
University of Arkansas Medical Sciences
Little Rock, AR

Anuj Mahindra, MD
Director, Malignant Hematology
Scripps Health
La Jolla, CA

Ravi Vij, MD, MBA  CHAIR
Professor of Medicine
Washington University School of Medicine in St. Louis
St. Louis, MO

Christopher Maisel, MD
Physician Oncologist
Baylor Sammons Cancer Centre
Dallas, TX

Andrew Yee, MD
Oncologist
Massachusetts General Hospital
Boston, MA

Thomas Martin, MD
Clinical Professor of Medicine
UCSF Medical Center
San Francisco, CA
### Friday, August 23, 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:30 PM</td>
<td>Welcome and Introductions</td>
</tr>
<tr>
<td>4:40 PM</td>
<td>GENETICS AND DIAGNOSTICS</td>
</tr>
<tr>
<td>4:40 PM</td>
<td>New Genomic Prognostic Markers: How to use Current Data to Determine Treatment</td>
</tr>
<tr>
<td>4:50 PM</td>
<td>Advances in the Understanding of Mechanisms of Resistance in Myeloma</td>
</tr>
<tr>
<td>5:00 PM</td>
<td>Genomic Discovery and Clonal Tracking: Cell-free DNA Sequencing</td>
</tr>
<tr>
<td>5:10 PM</td>
<td>The Presence of Large Focal Lesions as a Strong Independent Prognostic Factor</td>
</tr>
<tr>
<td>5:20 PM</td>
<td>Immune Signatures Associated with Improved Outcomes in Patients Post-AHSCT</td>
</tr>
<tr>
<td>5:30 PM</td>
<td>DISCUSSION</td>
</tr>
<tr>
<td>6:00 PM</td>
<td>TRANSPLANTATION AND CELLULAR THERAPIES</td>
</tr>
<tr>
<td>6:00 PM</td>
<td>Role of Auto Transplant in 2020</td>
</tr>
<tr>
<td>6:10 PM</td>
<td>How to Go Beyond Lenolidomide Maintenance</td>
</tr>
<tr>
<td>6:20 PM</td>
<td>Timing of CAR-T Therapy for Myeloma</td>
</tr>
<tr>
<td>6:30 PM</td>
<td>DISCUSSION</td>
</tr>
<tr>
<td>7:00 PM</td>
<td>ADJOURN TO RECEPTION</td>
</tr>
</tbody>
</table>

### Saturday, August 24, 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM</td>
<td>BREAKFAST</td>
</tr>
<tr>
<td>8:00 AM</td>
<td>TOPICS OF SPECIAL CONSIDERATION</td>
</tr>
<tr>
<td>8:00 AM</td>
<td>To Treat or Not to Treat Smoldering Myeloma: Lenalidomide vs. Daratumumab</td>
</tr>
<tr>
<td>8:10 AM</td>
<td>Relevance of NGS for Determination of MRD</td>
</tr>
<tr>
<td>8:20 AM</td>
<td>What is the Current Definition of Smoldering Myeloma and High-risk Smoldering Myeloma?</td>
</tr>
<tr>
<td>8:30 AM</td>
<td>Renal Involvement in Monoclonal Gammopathies: Evolving Treatment Options</td>
</tr>
<tr>
<td>8:40 AM</td>
<td>DISCUSSION</td>
</tr>
<tr>
<td>9:10 AM</td>
<td>BREAK</td>
</tr>
</tbody>
</table>

### GENETICS AND DIAGNOSTICS

- **4:40 PM** New Genomic Prognostic Markers: How to use Current Data to Determine Treatment
- **4:50 PM** Advances in the Understanding of Mechanisms of Resistance in Myeloma
- **5:00 PM** Genomic Discovery and Clonal Tracking: Cell-free DNA Sequencing
- **5:10 PM** The Presence of Large Focal Lesions as a Strong Independent Prognostic Factor
- **5:20 PM** Immune Signatures Associated with Improved Outcomes in Patients Post-AHSCT
- **5:30 PM** DISCUSSION

### TRANSPLANTATION AND CELLULAR THERAPIES

- **6:00 PM** Role of Auto Transplant in 2020
- **6:10 PM** How to Go Beyond Lenolidomide Maintenance
- **6:20 PM** Timing of CAR-T Therapy for Myeloma
- **6:30 PM** DISCUSSION
- **7:00 PM** ADJOURN TO RECEPTION
Expert Forum on MULTIPLE MYELOMA

For more information visit omionc.com